Dachaigh › Aillse Sgamhain Neo-chealla-beag › Texas › San Antonio
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an San Antonio, TX
Tha 59 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air San Antonio (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of ZW251 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- START San Antonio, San Antonio
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- START - San Antonio, San Antonio
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A’ fastadhÌre 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A’ fastadhÌre 1
- University of Texas San Antonio (UTSA), San Antonio
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology, San Antonio
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A’ fastadhÌre 3
- Texas Oncology - San Antonio Medical Center, San Antonio
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A’ fastadhÌre 3
- Texas Oncology - San Antonio, San Antonio
- Local Institution - 0381, San Antonio
A Study of PHN-012 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- PHN-012-001 Site, San Antonio
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Texas Oncology San Antonio Northeast, San Antonio
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- USO - Texas Oncology - San Antonio, San Antonio
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A’ fastadhÌre 3
- Texas Oncology - San Antonio, San Antonio
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A’ fastadhÌre 2/3
- Local Institution - 0173, San Antonio
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
A’ fastadhÌre 1/2
- START San Antonio (STSA), San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A’ fastadhÌre 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
A’ fastadhÌre 1/2
- START South Texas Accelerated Research Therapeutics, San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A’ fastadhÌre 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
A’ fastadhÌre 1/2
- START San Antonio, San Antonio
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2/3
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A’ fastadhSgrùdadh amharc
- The University of Texas Health Science Center at San Antonio, San Antonio
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A’ fastadhÌre 1
- Site 102 - START San Antonio, San Antonio
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
A’ fastadhÌre 1/2
- START | San Antonio, San Antonio
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology, San Antonio
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A’ fastadhÌre 1
- South Texas Accelerated Research Therapeutics, San Antonio
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
A’ fastadhÌre 1/2
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A’ fastadhÌre 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- START San Antonio, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- UT Health Mays Cancer Center, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Clinical Trial Site, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- START - San Antonio, San Antonio
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A’ fastadhÌre 1/2
- NEXT Oncology, San Antonio
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- Next Oncology, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
A’ fastadhÌre 1
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
A’ fastadhÌre 1
- New Experimental Therapeutics of San Antonio LLC, San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
A’ fastadhÌre 3
- Jason Bates at University of Texas Health Science Center, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
A’ fastadhÌre 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A’ fastadhÌre 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Texas LLC - San Antonio, San Antonio
- Start San Antonio, LLC, San Antonio
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- Research Site, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A’ fastadhÌre 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- START, San Antonio
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A’ fastadhÌre 1
- NEXT Oncology, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
A’ fastadhÌre 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A’ fastadhÌre 1/2
- Next Oncology, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- NEXT Oncology, San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
A’ fastadhÌre 1/2
- NEXT Oncology, San Antonio
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A’ fastadhÌre 2
- NEXT Oncology, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Oncology, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
A’ fastadhÌre 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
A’ fastadhÌre 1/2
- Research Site, San Antonio
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- START San Antonio, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
A’ fastadhÌre 1/2
- START San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
A’ fastadhÌre 1/2
- Next Oncology, San Antonio, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A’ fastadhÌre 1
- Dren Investigational Site, San Antonio
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A’ fastadhÌre 1/2
- NEXT Oncology, San Antonio
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
- Seattle, WA53 sgrùdaidhean
Sgrùdaidhean eile ann an San Antonio
- Aillse a' bhroilleach47 sgrùdaidhean
- Aillse colorectal46 sgrùdaidhean
- Ailse metastatach44 sgrùdaidhean
- Aillse (gach seòrsa)41 sgrùdaidhean
- Obesity40 sgrùdaidhean
- Diabaitis Seòrsa 237 sgrùdaidhean
- Ro-throm34 sgrùdaidhean
- Cancer Ovarian31 sgrùdaidhean
- Cancer Pancreatic31 sgrùdaidhean
- Aillse Prostata28 sgrùdaidhean
- Ailse Endometrial27 sgrùdaidhean
- Ailseachadh nan Sgamhan26 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.